Cancer Immunology, Immunotherapy

, Volume 27, Issue 3, pp 246–254 | Cite as

Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432

  • Yoshinori Nio
  • Jacob Zighelboim
  • Jonathan S. Berek
  • Benjamin Bonavida
Original Articles


The in vitro sensitivity to rTNF, rIFN-α2, and OK-432 of 11 freshly derived human ovarian tumors and 2 established tumor cell lines was examined in a cytotoxic assay using the 51Cr release test. Nine fresh lines were sensitive to rTNF, 8 to OK-432, and only 2 were sensitive to rIFN-α2. Cytotoxicity by rIFN-α2 was of lesser magnitude than the cytotoxicity mediated by rTNF or OK-432. The time of exposure and the concentration of BRM required for maximal cytotoxicity varied from line to line. Two fresh tumor cell lines and 1 established cell line (PA-1) were sensitive to all 3 BRMs, while 2 other FOCs and 1 cell line (SKOV-3) were resistant to all BRMs. The remaining FOC showed an intermediate degree of sensitivity. These results demonstrate the existence of heterogeneity of ovarian carcinoma tumor cell lines to lysis by BRMs. Among the FOCs, the 2 endometrioid carcinomas tested were highly sensitive to rTNF, whereas the serous carcinomas were more sensitive to OK-432. Low grade tumors were more sensitive to BRM than high grade tumors, and tumor extension did not correlate with sensitivity to the BRM. When tumor targets were exposed to more than 1 BRM added either simultaneously or sequentially, the net cytotoxic effect achieved was usually inferior to the sum cytotoxicity obtained by each BRM alone. Furthermore, rTNF and OK-432 were cytostatic to most ovarian tumor cell lines examined. The results of this study demonstrate that certain BRMs exert a direct effect on fresh ovarian tumor cells independently of host factors. These findings suggest that in vitro screening of a patient's tumor cells for sensitivity to a particular BRM prior to therapy could be beneficial for the proper identification of patients most likely to benefit from the treatment.


Tumor Cell Line Ovarian Carcinoma Serous Carcinoma Established Cell Line Endometrioid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albert DS, Moon TE, Stephens RA, Wilson H, Oishi N, Hilgers RD, O'Toole R, Thigpen JT (1979) Randomized study of chemoimmunotherapy for advanced ovarian carcinoma: A preliminary report of a Southwest oncology group study. Cancer Treat Rep 63:325–331Google Scholar
  2. 2.
    Allavena P, Introna M, Sessa C, Mangioni C, Mantovani A (1982) Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells Natl Cancer Inst 68:555–562Google Scholar
  3. 3.
    Bast RC, Knapp RC (1984) Immunologic approaches to the management of ovarian carcinoma. Semin Oncol 11:264–274Google Scholar
  4. 4.
    Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC (1983) Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 43:1395–1401Google Scholar
  5. 5.
    Berek JS, Hacker NF (1984) Immunotherapy of gynecologic cancer. In: Deppe G (ed) Chemotherapy of gynecologic cancer. Liss AR, New York, pp 363–374Google Scholar
  6. 6.
    Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L, Zighelboim J, Bast RC (1985) Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol 152:1003–1010Google Scholar
  7. 7.
    Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasses LD, Bonnem EM, Spiegel RJ, Zighelboim J (1985) Intraperitoneal recombinant alpha-interferon for “salvage” immunotherapy in stage III epithelial ovarian cancer: A gynecologic oncology group study. Cancer Res 45:4447–4453Google Scholar
  8. 8.
    Beutler B, Cerami A (1986) Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584–588Google Scholar
  9. 9.
    Bradley EC, Ruscetti FW (1981) Effect of fibroblast, lymphoid, and myeloid interferons on human tumor colony formation in vitro. Cancer Res 41:244–249Google Scholar
  10. 10.
    Carswell EA, Old LH, Kassel RJ, Green S, Fiore N, Williamson B (1970) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 80:5397–5401Google Scholar
  11. 11.
    Creasman WT, Gall SA, Blessing JA, Schmidt HJ, Abu-Ghazaleh S, Whisnant JD, DiSaia PJ (1979) Chemoimmunotherapy in the management of primary stage III ovarian cancer: A gynecologic oncology group study. Cancer Treat Rep 63:319–323Google Scholar
  12. 12.
    Ehrlich CE (1985) Clinical management of ovarian cancer. In: Roth LM, Czernobilsky B (eds) Tumors and tumor-like conditions of the ovary. Livingston, Churchill, New York, Edinburgh, London, and Melbourne, pp 247–268Google Scholar
  13. 13.
    Einhorn N, Cantell K, Einhorn S, Strander H (1982) Human leukocyte interferon therapy for advanced ovarian carcinoma. Am J Clin Oncol (CCT) 5:167–172Google Scholar
  14. 14.
    Epstein LB, Shen JT, Abele JS, Reese CC (1980) Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by in vitro semi-solid agar technique. Ann NY Acad Sci 350:228–244Google Scholar
  15. 15.
    Haranaka K, Satomi N, Sakurai A (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 31:263–267Google Scholar
  16. 16.
    Heicappell R, Naito S, Ichinose Y, Creasey AA, Lin LS, Fidler IJ (1987) Cytostatic and cytolytic effects of human recombinant tumor necrosis factor on human renal cell carcinoma cell lines derived form single surgical specimen. J Immunol 138:1634–1640Google Scholar
  17. 17.
    Helson L, Green S, Carswell E, Old LJ (1975) Effect of tumor necrosis factor on cultured human melanoma cells. Nature 258:731–732Google Scholar
  18. 18.
    Horning SJ, Merigan TC, Krown SE, Gutterman JU, Louie A, Gallagher J, McCravey J, Abramson J, Cabanillas F, Oettgen H, Rosenberg SA (1985) Human interferon alpha in malignant lymphoma and Hodgkin's disease. Cancer 56:1305–1310Google Scholar
  19. 19.
    Kasamatsu T, Ohmi K, Takeuchi S, Takamizawa H, Matsuzawa M, Kawana T, Ueda K, Kubo H, Tsumuji Y, Kawashima Y, Sugase M (1985) Clinical study of recombinant interferon alpha-2 (SCH 30500) in advanced gynecological cancers. Jpn J Cancer Chemother 12:1656–1660Google Scholar
  20. 20.
    Kawagoe K, Masuda H (1986) Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432. Jpn J Clin Oncol 16:137–142Google Scholar
  21. 21.
    Laszlo J, Goldstein D, Vugrin D, Hood L, Tso CY (1986) Does maintenance therapy with alpha interferon stabilize cancer growth? A pilot study. J Biol Response Modif 5:294–299Google Scholar
  22. 22.
    Ludwig H, Swetley P (1980) In vitro inhibitory effect of interferon on colony formation of myeloma stem cells. Cancer Immunol Immunother 9:139–143Google Scholar
  23. 23.
    Mannel DN, Moore RN, Mergenhagen SE (1980) Macrophages as a source of tumoricidal activity (tumor necrotizing factor). Infect Immunun 30:523–530Google Scholar
  24. 24.
    Matthews N, Watkins JF (1978) Tumor-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties, Br J Cancer 38:302–309Google Scholar
  25. 25.
    Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastasis with LAK cells and recombinant interleukin 2. Science 205:1487–1489Google Scholar
  26. 26.
    Nakano K, Sohmura Y (1986) Recombinant human tumor necrosis factor I. Cytotoxic activity in vitro. Int J Immunopharmacol 8:347–355Google Scholar
  27. 27.
    Nakazawa S, Yoshino J, Ohta H (1986) Endoscopic injection of OK-432 into gastric cancer in combination with systemic immunotherapy: A clinical study. In: Tobe T (ed) New application of OK-432, Excerpta Medica, Tokyo, pp 55–56Google Scholar
  28. 28.
    Otha M, Kano T, Nishida Y, Sakakibara K, Ishihara T, Tomoda Y, Miyazaki T, Arii Y, Umemura S, Tokuhashi Y, Okamoto M, Iida S, Saeki A, Kobayashi I, Imai N, Hayashi H, Maruyam T, Nakashima N (1986) Effects of immunotherapy using the nonspecific immunopotentiator OK-432 for malignant ovarian tumors: selection of appropriate cases for immunotherapy. In: Ohta K (ed) Clinical application of OK-432 for control of cancer, Excerpta Medica, Tokyo, pp 193–202Google Scholar
  29. 29.
    Quesada JR, Hawkins M, Horning S, Alexanian R, Bordon E, Merigan T, Adams F, Gutterman JU (1984) Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med 77:427–432Google Scholar
  30. 30.
    Rambaldi A, Introna M, Colotta F, Landolfo S, Colombo N, Mangioni C, Mantovani A (1985) Intraperitoneal administration of interferon in ovarian cancer patients. Cancer 56:294–301Google Scholar
  31. 31.
    Rosenberg SA, Lotze MT, Mulé LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Sepp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N Engl J Med 313:1485–1492PubMedGoogle Scholar
  32. 32.
    Salmon SE, Durie BGM, Young L, Liu RM, Trown PW, Stebbing N (1983) Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217–225Google Scholar
  33. 33.
    Sano H, Nakanishi Y, Sasaki F, Une Y, Hata Y, Uchino J, Kasai Y (1981) Direct antitumor effect of immunopotentiators on hepatoma and their influence on cell cycle. Jpn J Cancer Chemother 8:778–783Google Scholar
  34. 34.
    Shu S, Chou T, Rosenberg SA (1986) In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol 136:3891–3898Google Scholar
  35. 35.
    Smalley RV (1986) Interferon in the treatment of cancer. Med Clin North Am Suppl: 31–36Google Scholar
  36. 36.
    Sugarman BJ, Aggarwal BB, Hass PE, Figari IR, Palladino Jr MA, Shepard HM (1985) Recombinant human tumor necrosis factor: Effects on proliferation of normal and transformed cells in vitro. Science 230:943–945Google Scholar
  37. 37.
    Thigpen T, Blessing JA (1985) Current therapy of ovarian carcinoma: An overview. Semin Oncol 12:47–2Google Scholar
  38. 38.
    Torisu M, Katano M, Kimura Y, Itoh H (1983) Approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93:357–364Google Scholar
  39. 39.
    Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey III TJ, Zentella A, Albert JD, Shires GT, Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474Google Scholar
  40. 40.
    Uchida A, Hoshino T (1980) Clinical studies on cell-mediated immunity in patients with malignant disease: I. Effects of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 53:478–483Google Scholar
  41. 41.
    Uchida A, Micksche M (1983) Intrapleural administration of OK-432 in cancer patients: Activation of NK cells and reduction of suppressor cells. Int J Cancer 31:1–5Google Scholar
  42. 42.
    Uchida A, Micksche M (1983) Lysis of fresh tumor cells by autologous peripheral blood and pleural effusion lymphocytes activated by OK-432. J Natl Cancer Inst 71:673–680Google Scholar
  43. 43.
    Watanabe Y, Iwa T (1984) Clinical value of immunotherapy for lung cancer by the streptococcal preparation, OK-432. Cancer 53:248Google Scholar
  44. 44.
    Williamson BD, Carswell EA, Rubin BY, Prendergart JS, Old LJ (1983) Human tumor necrosis factor produced by human B-cell lines: Synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 80:5397–5401Google Scholar
  45. 45.
    Yamamura Y, Yasue M, Nakazato H, Suchi T, Ota K (1986) A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: Fourth study. In: Ota K (ed) Clinical application of OK-432 for control of cancer. Excerpta Medica, Tokyo, pp 1–9Google Scholar
  46. 46.
    Yanagawa T, Ogura M, Takagi T, Takenaga K (1984) Direct antitumor activity of biological response modifiers (B.R.M.) proven by an in vitro sensitivity test. Jpn J Cancer Chemother 11:2155–2162Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • Yoshinori Nio
    • 1
  • Jacob Zighelboim
    • 1
  • Jonathan S. Berek
    • 2
  • Benjamin Bonavida
    • 1
  1. 1.Department of Microbiology & Immunology, UCLA School of MedicineUniversity of California at Los AngelesUSA
  2. 2.Department of Medicine and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UCLA School of MedicineUniversity of California at Los AngelesUSA

Personalised recommendations